Furthermore, our current findings suggest that the expression of tumor cell-intrinsic cGAS–STING, along with MMR/MSI status, could be a novel biomarker predicting the efficacy of immunotherapy using ICIs in GC. The gene discussed is STING1; the disease is neoplasm.